☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Samsung Bioepis
The CHMP Grants Positive Opinion to Samsung Bioepis and Biogen’s Opuviz (Biosimilar, Eylea)
September 23, 2024
Samsung Bioepis Reports the US FDA’s Approval of Epysqli (Biosimilar, Soliris)
July 23, 2024
Samsung Bioepis Reports the US FDA’s Approval of Pyzchiva (Biosimilar, Stelara)
July 1, 2024
Samsung Bioepis Reports the Initiation of the P-I Trial Evaluation of SB27 (biosimilar, pembrolizumab) for the Treatment of Lung C...
March 4, 2024
Samsung Bioepis Highlights 2 Abstracts for SB17 (biosimilar, ustekinumab) for the Treatment of Moderate-to-Severe Psoriasis at ECC...
February 22, 2024
Samsung Bioepis Signs a Collaboration Agreement with Samil Pharma to Co-Commercialize SB15 (biosimilar, aflibercept) for the Treat...
February 1, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.